Lunai Bioworks (NASDAQ:LNAI) Stock Price Up 5.1% – Time to Buy?

Shares of Lunai Bioworks Inc. (NASDAQ:LNAI) were up 5.1% on Thursday . The company traded as high as $2.39 and last traded at $2.28. Approximately 28,489 shares were traded during mid-day trading, a decline of 11% from the average session volume of 32,102 shares. The stock had previously closed at $2.17.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on LNAI shares. Wall Street Zen raised shares of Lunai Bioworks to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Lunai Bioworks has an average rating of “Sell”.

Lunai Bioworks Stock Up 2.2%

The stock has a market cap of $10.55 million, a P/E ratio of -5.83 and a beta of 0.35. The company’s 50 day moving average price is $2.38 and its two-hundred day moving average price is $2.65.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.